Disability progression in relapsing MS tends to follow one of four distinct patterns, according to a new study.

Lipoic acid offers no improvements in walking speed or other outcomes in patients with progressive multiple sclerosis ...

Children with MS who have more paramagnetic rim lesions, or chronic inflammation, tend to show faster declines in brain ...

Environmental exposures are emerging as major contributors to autoimmune risk: Studies link air pollution, PFAS, and ...

French drugmaker Sanofi on Monday flagged another delay to a U.S. regulatory decision for its experimental multiple sclerosis ...

Annual out-of-pocket treatment costs for multiple sclerosis increased by 125% from 2002 to 2021 in the US, driven mainly by ...

A disability enterprise is partnering with Australia Post to deliver mail to Aboriginal town camps around Alice Springs.

Sanofi’s PERSEUS phase 3 study of tolebrutinib in primary progressive multiple sclerosis fails to meet primary endpoint: Paris Tuesday, December 16, 2025, 11:00 Hrs [IST] Sanofi ...

Sanofi provides update on tolebrutinib in primary progressive multiple sclerosisPERSEUS phase 3 study in primary progressive multiple sclerosis ...

Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis: Paris Friday, December 26, 2025, 13:00 Hrs [IST] The US Foo ...

A recent large-scale study shows how sticking to a Mediterranean diet may lower the risk of developing multiple ...